Intravitreal anti-vascular endthelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
Dahr SS et al（ML USA)
Retina 27(2): 150-8, 2007
・von Hipple-Lindau (VHL)病の強い浸出のある患者5名で pegaptanib 3mg/0.1mlを6週間毎に最低6回、硝子体内注入を行い、有効であった